Symbiosis secures FDA viral vector process approval5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.
Symbiosis Pharmaceutical Services has reported FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK.
Symbiosis recently hosted a successful inspection by the FDA for the aseptic manufacture of viral vector products for commercial supply into the US market at its GMP manufacturing facility, which has been licensed by the UK government's regulators, the MHRA, since 2012.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, commented: “The approval of this process at Symbiosis by the FDA is testament to our technical experience, capabilities, and specialist understanding of viral vector filling in compliance with the highest of regulatory standards.
“We have been honing our niche viral vector handling and manufacturing skills for several years and have dedicated resource and effort to maintaining the strict quality standards and expertise required to make the commercial GMP sterile filling of viral vectors a core capability at Symbiosis.
“This FDA inspection milestone is directly supportive of our recently reported success in being awarded a £1.9 million (US$ 2.4 million) grant from the UK government's funding body, Innovate UK, which was directed at strengthening the position of Symbiosis as a centre of excellence as part of the viral vector drug development supply chain, and firmly consolidating the commercial viral vector manufacturing capability of the UK as a global leader in this field.
“The FDA approval of Symbiosis, alongside its Innovate UK grant success, represents a significant positive indicator which supports the development of world-leading capabilities for clinical and commercial production of gene and immunotherapy viral vector drug substance and drug product manufacturing in the UK.”
MacKay continued: “Our ability to offer rapid access to sterile manufacturing slots has been a key competitive differentiator compared with the larger CDMOs in the outsourcing marketplace and has succeeded in leading to long-term relationships being built with pre-clinical, Phase I-III, and now commercial-stage biotech and pharma companies worldwide.”
SIRIO Pharma opens multimillion gummy production plant
18 Oct 2018
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.Read more
Tjoapack and Veratrak launch EPOCH initiative
17 Oct 2018
The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.Read more
Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site
16 Oct 2018
The investment increases the overall capacity and capabilities of the facility, and its flexibility.Read more
Particle Sciences to open new commercial facility
15 Oct 2018
New facility will offer customers the full range of services from development through to commercial-scale manufacturingRead more
Generics companies to move away from "little white pills"
14 Oct 2018
Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.Read more
Pharma manufacturers warned to invest in continuous manufacturing
11 Oct 2018
CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.Read more
New portable and ready-to-use upper respiratory drug delivery solution
11 Oct 2018
PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.Read more
CPhI Worldwide announces the winners of the 15th Pharma Awards
10 Oct 2018
17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Micro-Sphere increases capsule filling capacity
8 Oct 2018
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation